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ABSTRACT
Biodegradable alginate microcapsules (MC) are recently becoming widely used in 
the biomedical field, and have shown effectiveness as a drug delivery system. Alginate 
has been used in microencapsulation due to its simple gelling process, biodegradability, 
excellent biocompatibility, and its stability under in-vivo conditions. Alginate polymer is 
a natural polysaccharide derived from brown seaweed and has the ability to polymerize 
rapidly in the presence of cations to form a porous matrix. In order to advance the 
previous system for efficient protein and peptide delivery, we further lyophilized the 
peptide-filled microcapsules and we were able to rehydrate, and test them for sustained 
release. Electrospray method, as a microencapsulation technique, has been previously 
used to encapsulate peptides and proteins successfully using alginate. A second coating 
of poly-l-ornithine (PLO) polymer can be used to increase the integrity of alginate 
microcapsules. Alpha-carboxy terminus 1 (αCT1) peptide, Human platelet lysate (HPL), 
and bovine serum albumin (BSA) were examples of peptides and proteins that were 
successfully encapsulated by our lab.  
Cell-based therapies represent a revolutionary bio-technique that has been applied 
widely in medicine. Recently, they have been successfully applied in treatment of 
neurodegenerative diseases, eye diseases, cardiovascular disease, diabetes, liver disease 
and cancer. Suppression of the host immune system is considered the main challenge in 
such therapies. In order to avoid the side effects of immunosuppressive drugs, 
 vi 
encapsulating cells into polymeric matrices is considered a promising strategy. 
Encapsulation systems utilize permeable materials that allow diffusion of nutrients, waste 
and therapeutic factors into and out of cells, while masking the cells from the host 
immune response. In our model, we have been encapsulating ARPE-19, human immortal 
cell line, that was genetically designed to express and secret CR2-fH protein to test them 
for safe and effective long term inhibition in vivo. CR2-fH is a complement inhibitor 
molecule that has been recently found to express promising therapeutic effects in both in 
vivo and in vitro models of Age-related Macular degeneration (AMD). Furthermore, 
human skeletal muscle differentiating cells (skMDC) that were recently used in 
biomedical research to investigate skeletal muscle behavior, function, and ability to be 
implemented in tissue regeneration field for further applications of disease advanced 
therapies. 
In this study we hypothesize that alginate encapsulation using high voltage 
method can be enhanced and advanced further to use it in different clinical approaches 
and applications. The present study shows the successful formation of alginate-poly-L-
ornithine microcapsules using the above-mentioned method, according to specific 
parameters, to produce microcapsules about 200 m in diameter. The microcapsules 
derived from this encapsulation technique according to our hypothesis can be freeze dried 
without harming the shape of the microcapsules in which they retain the original shape 
after hydration. The main purpose of lyophilization is to increase the shelf-life storage of 
encapsulated biomaterials as well as preserve its activity to be used for treatment. 
Moreover, the technique has the ability to preserve the metabolic activity of genetically 
engineered ARPE-19 cells and skMDC cells resulting in effective and safe long-term 
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drug delivery for treatment. In addition, hydrogel systems have been utilized in 
combination with the previous approaches, lyophilized microcapsules and encapsulated 
cells, for more improvements in regenerative medicine and targeted delivery therapy 
fields. 
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CHAPTER I 
INTRODUCTION
1.1 Microencapsulation and Drug Delivery Systems 
Drug delivery systems (DDS) are engineered approaches or technologies for 
controlled release of therapeutic agents and/ or delivery of them to target organs in the 
body in order to eliminate or minimize systemic side effects. Recently, DDS have been 
improved steadily, and the interest in controlled release dosage forms has increased. DDS 
that include carriers, composed mainly from lipids and/or polymers, and their associated 
therapeutic agents on macro, micro, and nano scale are primarily designed to manipulate 
biodistribution and pharmacokinetics of the associated drugs. In addition, DDS are 
functioning as sustained release systems especially with advances in biotechnology 
related to macromolecules such as proteins, peptides, oligonucleotides, and plasmids 
1,2
. 
Microencapsulation systems are one of DDS that are recently getting more 
attention in advancement for targeted delivery of therapeutic agents. Microcapsules 
yielded from this technique are characterized by their semipermeable membrane that 
allows diffusion of the encapsulated materials from the inner core. The permeability of 
the microcapsules can be adjusted by coating with one or more layers which provide a 
controlled release property or add protection of the encapsulated materials. There is a 
diversity of materials that can be encapsulated successfully for different clinical 
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applications such as peptides, proteins, enzymes, and antibiotics. Properties of 
microcapsules (size and shape) are controlled by different parameters such as applied 
voltage, spraying distance, flow rate, method of encapsulation, and polymer 
concentration
3
. The synthesis procedures can vary such as electrospray method, 
emulsification, jet flow, and solvent evaporation; which result in microcapsules with 
different morphologies and shapes including spheres, cubes, rods, and irregular patterns
3–
5
. There are two main categories in the field of electro-hydrodynamics: electro-spraying 
and electro-spinning.  
Microparticles, as drug delivery systems, have been developed due to the 
advancement of pharmaceutical materials technology that allowed creation of polymeric 
microcapsules using electrically charged fluids of different natural and synthetic 
polymers. The polymeric microcapsules have distinctive properties in terms of shape, 
particle size, drug loading, and profile release
6
. Currently, there are a wide range of 
polymers that are used for microencapsulation technology including sodium alginate, 
chitosan, poly-lactic-co-glycolic acid (PLGA), poly-ethylene glycol (PEG), poly-l-
ornithine (PLO), and poly-l-lysine (PLL)
7–12
. Unique properties of each polymer such as 
biocompatibility, viscosity, reactivity with the encapsulated materials, and charge; make 
it unique for its desired application. 
All the different encapsulation procedures share the same methodology concept. 
One of the polymers used for encapsulation is placed in a positively charged syringe 
attached to a high voltage generator, and the flow rate of the polymer is controlled by 
using a syringe driver or pump where the polymer is extruded to a grounded gelling bath. 
A cone jet is formed at the needle tip due to application of an electric polarization stress 
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(electrically conductive solution passes through electrical potential difference), flow and 
gravity. The cone jet is a formation of conical shape of liquid at the needle tip where the 
charged particles of the liquid accumulate at the apex of the cone. Once a minimal steady 
state has been reached of both flow and electrostatic voltage, the charged particles 
separate from the apex and break into reproducible droplets. The material’s nature and 
properties plays main role in this stage of the procedure
13,14
. Without applying electrical 
forces to the procedure, the droplet will be controlled by the surface tension of the liquid 
polymer and effect of the gravity
15
. The formed droplet, as micro or nanoparticles, will 
finally be collected in a grounded solution (as in electrospray method) or device (as in 
electrospinning method). Both methods are becoming more popular as methods of drug 
delivery because they can be easily adjusted or altered to form particles possessing a 
desired release rate and pharmacokinetics. On the other hand, other methods of 
encapsulation may require additional steps such as heat, shear stress, and pressure which 
might negatively affects the encapsulated therapeutic agents by decreasing its 
functionality or degrading its structure
3
. Our method of interest in this work is the 
electrospray method to produce spherical microcapsules using sodium alginate as a 
primary polymer. 
Alginate is a natural polymers and it is used widely in microcapsule formation 
because of its unique properties including low toxicity, biocompatibility, mechanical 
stability, bioadhesive properties, gelling properties and abundance
2,16,17
. It is a naturally 
occurring polysaccharide extracted from brown seaweed, and it’s chemical structure is 
composed from a linear copolymer of (1–4)-linked β-D-mannuronic acid and α-L-
guluronic acid as it is described in Figure 1.1 
10,18–23
. Different applications of alginate 
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has been explored such as its usage as coating material, preparation of controlled release 
drug delivery systems including microspheres, gels, and membranes; as well as forming a 
hydrogel when crosslinked to cations such as calcium of barium
16,24,25
.  
1.2 Freeze drying—Lyophilization  
Lyophilization, or freeze drying, is a technique often used mainly to enhance the 
stability and shelf life of pharmaceutical products. This technique is based on dehydrating 
a pre-frozen material at low temperature and low pressure, and resulting in formation of a 
porous structure. In addition to preserve color, scent, and shape of lyophilized materials, 
freeze drying technique keeps the biochemical characteristics and pharmacological 
properties to the greatest extent. Freezing and drying stresses applied by lyophilization 
could tend to destabilize or denature protein compounds, but different proteins endure 
freezing and drying stresses to various degrees. Although lyophilization of protein 
formulations is a challenging process, it is considered a common procedure in the 
pharmaceutical field to improve stability of therapeutic proteins especially to maintain 
their original characteristics upon reconstitution
26–29
. Freeze drying has been used 
previously to dehydrate proteins, plasma, vaccines, blood platelets, and sperm cells and it 
has been shown to increase their shelf-lives
29–34
. Also, seeking activity preservation of 
most biological materials containing live bacteria and viruses through freeze drying 
become widely used to ensure long term preservation. 
The lyophilization process is typically performed initially by freezing the 
biological material to freezing temperature range of (-50C)-(-80C), followed by drying 
the biological material under vacuum to remove frozen water from the material at two 
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different stages of drying. Primary drying at temperatures below 0C and the drying rate 
at this stage is limited to avoid foaming of the product due to the high temperature and 
the excess liquid (solvent) amount at this stage. Then the secondary drying stage begins 
at temperatures above 0C to bring the residual moisture of the biological material to an 
optimum level. If the moisture content is above or below the optimum value, the effective 
life of biological material will be reduced
35–37
. 
 Freeze drying of microencapsulated human retinal pigment epithelial cells 
(ARPE-19) has been shown to be successful in a recent study
38
. It has been demonstrated 
that the cells were able to retain their viability and structural integrity after freeze 
drying
39
. Cell were encapsulated in polycation coated alginate microcapsules and 
lyoprotective solutions such as trehalose that protects proteins, cellular membrane, and 
nucleic acids from the harmful effects of the dehydration
32,40–43
. Trehalose replaces the 
cellular water molecules and forms intracellular glass to protect the viability of the cells 
from the damage that can be caused by the dehydration. Also sugars and antioxidants can 
be added in different protocols for the same protection purposes
43–47
. 
1.3 Cell encapsulation 
 Cell encapsulation technology refers to entrapment of living cells as targeted 
delivery systems. Encapsulated cells can be used for two purposes: delivering living, 
functional cells to the target organs for tissue engineering purposes; delivering 
therapeutic molecules produced from genetically engineered cells to a targeted tissue or 
organ. More important, this technique provides the advantage of long term targeted 
treatment without the necessity for recurrence. As described in Figure 1.2, cells after 
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encapsulation will be entrapped within a polymeric semipermeable membrane that allow 
influx of nutrients and oxygen; and outflux of metabolic waste products and therapeutic 
molecules. The membrane also protects the cells from the host immune system
48
. 
 Cell encapsulation technique is a promising approach in the development of cell 
based therapies to treat acute and chronic illnesses. Recently, research studies are focused 
on encapsulating different cell types such as ARPE-19 cells, peripheral blood 
mononuclear cells, non-human primate multipotent stromal cells, mesenchymal stem 
cells, and islet cells
39,49–52
. Alginate polymer is widely used in encapsulating different 
types of cells and the purification degree of alginate is playing a great role in the success 
of cell encapsulation process. It has been shown that poorly purified alginate resulted in 
failure of many microencapsulation processes; indeed, ultra-purified raw product (clinical 
grade) of alginate in combination with PLO showed to be highly proficient in rendering 
immunity stimulation of the host body where the mannuronate dimeric blocks of alginate  
covalently bound to PLO
49
.  
 In a previous clinical study it has been shown that cells encapsulated within 
alginate/PLO fabricated microcapsules had enough durability and robustness over a long 
period of time lasts up to 5 years without any immunity sensitization
49
. The team of this 
study was able to retrieve physically intact microcapsules after 5 years post-transplant 
from one of the patients with type I diabetes included in the study. Although the study 
was successful in transplanting encapsulated islet cells in diabetic patients for a long 
period of time without any adverse effects, no therapeutic effect has been recorded 
including regeneration of native islet cells or downregulation of plasma glucose levels. 
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However, such a successful clinical study brings motivation and hope that this technique 
can be developed to play a vital role in cell targeted therapy in the near future
49
. 
1.4 Hydrogel 
 Hydrogels are composed of hydrophilic polymer chains that form a three-
dimensional system with high water content. The characteristics and properties of each 
hydrogel depend on the type of polymer used to prepare it, and also can define the 
purpose of use or the results to be pursued of each application. These properties are 
varied such as: biocompatibility, elasticity, capability to mimic extracellular matrix 
(ECM), and adaptable chemical properties
53–55
. Polymers used in preparing hydrogels are 
classified in two categories: naturally derived from materials such as collagen, alginate, 
chitosan, and hyaluronic acid or synthetically derived from materials such as poly 
hydroxyethyl methacrylate (poly HEMA) and poly ethylene glycol (PEG)
56,57
. Hydrogels 
are gaining attention in biomedical research field and regenerative medicine due to their 
ability to serve as cell and drug delivery therapies, and due to the advancement 
accomplished in biomaterial systems which set the foundation for therapeutic strategies 
54,58–62
.  
Stem cell therapy using hydrogel as a bioactive material is one of the important 
applications of hydrogel where it is known as regulation of stem cell fate in the field of 
cell delivery therapy. Hydrogels act as platform that allows better viability, proliferation, 
and retention of the stem cells
63–67
.  The similarity in the structure between hydrogel 
scaffolds and extracellular matrix of many tissues is beneficial and increases the 
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successfulness rate of this approach in engineering tissue replacements; as well as in drug 
and growth factor delivery
68
.  
Usage of natural polymers in preparing hydrogel scaffolds is becoming more 
popular in regenerative medicine recently. Collagen is considered one of the most 
commonly used natural polymers in this field due to its biocompatibility, 
biodegradability, and high versatility
69–71
. It is one of the main components of 
extracellular matrix proteins existing in the mammalian tissue, and it is derived from skin 
and tissue of vertebrate species
67,72,73
. It has been shown previously that type I collagen 
based hydrogels can cooperate with polyacrylamide to create matrix models of scars 
which considered soft matrices that exhibit less cell to cell noise. Moreover, type I 
collagen is able to covalently cross-link to protein patterns to stimulate interactions 
between the hydrogel surface and the cells
74,75
. Collagen hydrogels have been used with 
great success as three-dimensional media for cell culture and showed promising results 
acting as scaffolds for engineered tissues and tumors. More important, adjustment of 
quantitative characteristics of collagen hydrogel properties is a critical phase to fulfill 
engineering requirements and match specific tissues in order to be considered as viable 
tissue mimics
76
.   
 My studies aim to further investigate different approaches to test the hypothesis 
that microencapsulation technique is a unique tool or device which could be advanced to 
fulfill the necessity of different clinical applications and therapies. These studies are 
described in the following chapters:       
 9 
 Chapter II: The role of lyophilization process in advancing microencapsulation 
technique. 
 Chapter III: The effect of electrospray method of encapsulation on the viability of 
living cells within alginate based microcapsules. 
 Chapter IV: Involvement of hydrogel systems in advancing alginate based 
microcapsules.  
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Figure 1.1 The chemical structure of sodium alginate polysaccharide building units. 
 (G) Glucuronic acid, and (M) Mannuronic acid. Image produced by the Food and 
Agriculture Administration of the United Nations. 
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Figure 1.2 Schematic illustration of cell encapsulation technology. 
(Reproduced with permission from Bhujbal SV, de Vos P, Niclou SP. Drug and cell 
encapsulation: Alternative delivery options for the treatment of malignant brain tumors. 
Advanced Drug Delivery Reviews. 2014;67-68:142-153. doi:10.1016/j.addr.2014.01.010) 
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CHAPTER II 
THE ROLE OF LYOPHILIZATION PROCESS IN ADVANCING 
MICROENCAPSULATION TECHNIQUE
1
 
 
2.1 Background 
Targeted drug delivery and controlled release delivery are considered key areas in 
drug delivery systems. Advancements in technology are becoming more focused on 
precisely targeting therapeutic agents to the exact cell, tissue, or organ; and in controlling 
the fate of a therapeutic agent entering the body
77
. The encapsulation method is a major 
factor in encapsulation and release of therapeutic agents. Other factors also control the 
characteristics of microcapsules; the type of polymer icluding its molecular weight, 
viscosity, and surface charges contribute in defining its characteristics as well as the 
characteristics of formed microcapsules
78
. Using electrospray method as a method of 
fabrication of polymers is the method of choice in this study. Also, alginate is the core 
polymer used to form microcapsules in adjacent to poly-l-ornithine which is used as a 
double coat to increase the integrity and enhance the selective porosity of the 
microcapsules
79,80
. In this work, we hypothesized that lyophilization of A-PLO 
microcapsules might advance this technology and enhance its usage for a variety of 
applications.
                                                          
1
 Parts of this chapter have been excerpted from the following research article: 
Belhaj M, Menon V, Rohrer B, Potts J. Alginate Microcapsule Technology and Impacts 
on Cell Therapy Development. Microsc Microanal. 2017;23(S1):1214-1215. 
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 Lyophilization is a process that operates at different conditions and temperatures 
which may result in products with different characteristics
26,81,82
. However, lyophilization 
has been used widely to preserve different biological materials used for a variety of 
clinical purposes such as antibiotics, vaccines, proteins, and cells
31,35,36,45,83
. Moreover, 
lyophilization is a promising procedure in maintaining different therapeutics, including 
pharmaceuticals and biological materials, in a dry form for long-term storage, transport, 
and rehydration at the time of clinical administration
84
. 
2.2 Materials and Methods 
Microencapsulation:  
Electrospray Method was used to prepare the microcapsules
7,85,86
. Sodium 
alginate (Sigma-Aldrich, St. Louis, MO, USA) was mixed under sterile conditions at a 
concentration of 2% w/v. The resulting mixture was purified by filtration at 0.2 mm. 
Human platelet lysate (HPL) (Cook Biotech) was added to the alginate and small aliquots 
(280 mL) of filtered alginate and HPL mixture were loaded into a 3cc syringe and 
attached to a syringe pump. Alginate-poly-Ornithine (A-PLO) microcapsules were 
produced by a one-step method. Polymer solution of poly-l-ornithine (Alfa Aesar L-
ornithine hydrochloride 99%) was mixed at a 0.5% w/v in 0.15 M calcium chloride 
(CaCl2) (Sigma-Aldrich). The pH was buffered accordingly by 0.1 M HEPES. 
A volume of 30 mL of the gelling solution was placed in a beaker below the 
syringe pump as a gelling bath, with a needle-to-bath working distance of 7 mm (spray 
distance). A high voltage generator was attached to the tip of 30cc blunt tip needle 
(purchased by Amazon Supply, Seattle, WA, USA) with a ground placed in the CaCl2 
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solution. Next, a constant voltage was set on the high voltage generator to pass a field of 
current through the needle tip attached to the syringe. The syringe pump was started to 
push the filtered alginate solution through the needle tip and into the CaCl2 gelling bath 
with a flow rate of (60 mm/h). As the extruded alginate was pushed by the syringe pump, 
it passed through the positively charged needle into the negatively charged CaCl2 gelling 
bath creating spherical microcapsules. The voltage remained constant throughout the 
microcapsulation process by setting the generator prior to starting the syringe pump. 
Synthesized microcapsules were allowed to gel 12 minutes then removed from the gelling 
bath post-synthesis and rinsed several times in sterile deionized water to remove any 
traces of CaCl2.  
Lyophilization of Microcapsules:  
Microcapsules were prepared as mentioned above. The suspended microcapsules 
in deionized water were frozen using liquid nitrogen. Once the sample was frozen, the 
beaker was covered with parafilm or a piece of foil and pierced many times to allow 
escaping of water vapor. Then the sample was placed into a lyophilizer vessel (Labconco, 
Kansas City, MO, USA) overnight to get a dry powder of microcapsules. The lyophilized 
microcapsules were rehydrated using deionized water and tested morphologically to 
ensure complete recovery and shape retaining. 
Scanning Electron Microscopy (SEM) of Microcapsules:  
It was performed to characterize surface morphology of lyophilized and non-
lyophilized microcapsules and examine the effect of lyophilization process on 
microcapsules morphology. Prior to SEM preparation, microcapsules from both groups 
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were exposed to UV power at 9,000 x 100 on a plastic petri dish for 30 minutes. An 
incubation of 24 hours at 4C was then allowed.  Exposure to UV power has been done to 
increase microcapsule rigidity that insures maintaining the shape during harsh SEM 
processing. The method of processing was carried out based on a modified protocol using 
the osmium-tannic acid osmium method (Murphy, 1980). A buffer of 0.1M Na 
cacodylate, 3mM CaCl2 at pH 7.2 was used initially to wash microcapsules followed by a 
buffered fix of 2% paraformaldehyde, 2% glutaraldehyde, and 0.1% ruthenium red.  
The microcapsules were then rinsed with (Na cacodylate/ CaCl2) buffer and 
placed in a secondary buffered fix consisting of 1% osmium tetroxide and 0.1% 
ruthenium red. The same buffer solution, (Na cacodylate/ CaCl2) buffer, was used to 
rinse fixed microcapsules, and then placed in a series of alternating buffered fixatives 
containing either 1% tannic acid in 1% glutaraldehyde or 1% osmium tetroxide. Rinses in 
these buffered fixatives were repeated eight times at 20 min each with rinsing with buffer 
in between steps. Finally, the microcapsules were rinsed with water to remove any buffer 
residues, followed by deydrating in a series of ethanol baths, critical point drying 
(Tousimis Samdri PVT 3B; Tousimis, Rockville, MD, USA), and gold sputter coating 
(Cressington 108 Auto/SE; Cressington Scientific Instruments Ltd., Watford, UK). SEM 
images were taken using a JEOL JSM-6300 SEM at 10 kV (JEOL Ltd., Tokyo, Japan). 
Microencapsulation and Release Profile of BSA Protein:  
 Release profiles of BSA were studied over 10 days from alginate microcapsules 
formation or from lyophilized microcapsules rehydration at different temperature 
settings, 37C and room temperature. In our studies we have elected to study release in 
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alginate microcapsules before lyophilization and rehydrated microcapsules after 
lyophilization. 
 For these experiments, encapsulation parameters were kept constant at 6.0kV 
initial voltage, flow rate of 60mm/hr, and 7 mm spray distance. Initial BSA protein 
concentration was kept constant at 1mg/ml. Alginate concentration was also kept constant 
at 2%, while the CaCl2 gelling bath was synthesized at 0.15M CaCl2 as previously listed. 
As it has been suggested in a previous study held in the lab, pH as well kept constant at 
7.3. Microcapsules used for release profiles were not coated with poly-l-ornithine 
polymer. Post synthesis, microcapsules were rinsed in deionized water to remove excess 
gelling solution. The microcapsules were then re-covered in 0.5mL deionized water, with 
time points taken over 10 days. Early time points of 1, 2, 4, 6, and 8hrs were taken to 
account for early burst release of peptide from the microcapsules. Analysis of peptide 
concentration was performed using a Micro BCA protein assay kit (Thermo Scientific) 
with BSA standard solution for our standard curve. All tests were run on a BioTek 
Synergy 2 spectrophotometer. 
2.3 Results 
 Microencapsulation technique in our lab has been performed using electrospray 
method under specific parameters to produce 200 m microcapsules in diameter. The 
voltage was 6.0 kV, the flow rate was 60 ml/hour, the spray distance was 7 mm, and 2% 
concentration of alginate solution. Also, the microcapsules were coated with poly-l-
ornithine to increase the integrity of alginate microcapsules. Before processing the 
microcapsules for electron scanning microscopy, the microcapsules were crosslinked 
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using ultraviolet cross linker to increase their stiffness in order for the microcapsules to 
maintain their shape during the preparation protocol for microscopy. As shown in Figure 
2.1 A, the microcapsules were spherical in shape at its hydrated state with an average 
diameter of 200 m. Microcapsules after encapsulation process were washed thoroughly 
to remove any traces of CaCl2; then the microcapsules were loaded into lyophilizer for 
dehydration. Dried microcapsules appeared as white powder, and its structure appeared to 
be shrunk when examined with light microscopy and SEM as it is shown in Figure 2.1 B. 
Adding deionized water to the lyophilized microcapsules led to its rehydration 
and regaining almost the original spherical shape compared to control microcapsules 
(before lyophilization). In Figure 2.1 C, rehydrated microcapsules appeared to have rough 
surface compared to control microcapsules; however, most of the microcapsules retained 
back their spherical appearance where very few rehydrated microcapsules get burst after 
rehydration.  
Loading efficiency experiments were conducted on four samples. Two identically 
synthesized sets of microcapsules, one used immediately after encapsulation process and 
one after rehydration following lyophilization, were both analyzed for release at 37C 
and room temperature. Our preliminary data in Figure 2.2, indicated a rapid initial burst 
of BSA prior to the initial 1 hour time point in the examined samples. Release from non-
lyophilized microcapsules at room temperature does not show the initial burst release, 
and it shows a delayed release until day 6 of incubation when it starts releasing. Previous 
reports have suggested that the insets of release are at the five hours of release for better 
appreciation of the rapid release of peptide
85
. The fluctuating release of BSA over all the 
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samples is not clear. The impact of lyophilization and incubation temperature on BSA 
release is unknown and must be further investigated in order to determine significance. 
2.4 Discussion 
 A-PLO microcapsules previously showed a great potential as a controlled release 
delivery system of connexin 43 peptide to increase wound healing rates in vivo
80,85
. 
Parameters of encapsulation procedure are what control the characteristics of the 
microcapsules produced. Nature and features of polymers have played an integral role in 
advancements of delivery systems which defines the characteristics of microcapsules.  
Accordingly, in this study we are using electrospray method to produce 
approximately 200 m microcapsules by adjusting alginate concentration, flow rate, 
spraying distance, and voltage rate. Our main goal is to optimize this technology and 
improve its versatility for variety of clinical applications; therefore, lyophilization is one 
of the approaches that will be examined in the current study. Lyophilization, freeze 
drying, has been utilized since 1958 to enhance the pharmaceutical products in order to 
be utilized at different administration strategies
87
.  
 As demonstrated through our results in Figure 2.1 that A-PLO microcapsules 
were successfully lyophilized; not only that but also they were able to retain their 
morphology back after rehydration. The microcapsules shown were empty, not loaded 
with any material. Proteins were one of the biological materials to be lyophilized 
successfully for stability and storage purposes. Although lyophilization was ideal to 
prepare solid protein pharmaceuticals achieving stability at acceptable storage shelf life; 
however, this process generates different stresses such as temperature changes, vacuum 
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forces, pH changes, and formation of ice crystals. Protein denaturation at various degrees 
might occur as a result of exposure to all of the stresses listed earlier
26,87
. Numerous 
research studies have been conducted to identify critical effects of protein lyophilization 
on protein stability and effectivity
37,82,88
. It has been shown that the need for stabilizers is 
very critical in maintaining encapsulated biological materials’ effectivity during freeze 
drying and storage afterwards as well as preserve the microcapsules structure
40,42,89
. The 
results shown in our study indicates that the lyophilization process was capable of 
preserving the original structure of our alginate-PLO microcapsules. However, further 
investigations needed to verify the effects lyophilization on characterizations of 
microcapsules which serve as controlled release delivery system. 
 Release profiles of biomaterials have proven to be controlled by different factors 
including encapsulation parameters and incubation environment. As a result, it has been 
previously shown that release of CT1, a low molecular weight peptide, can be 
controlled by altering extrusion parameters or by including an additional polymer coating 
to in order to interfere with diffusion pathway
85
. According to our preliminary data, the 
effect of lyophilization on release of BSA is not clearly understood. In addition, the 
change in incubation temperature presumed to have an effect that was not clearly 
correlated to the control of BSA release from alginate microcapsules. Further 
investigations are highly recommended to identify a clear vision on the effect of 
lyophilization on releasing of encapsulated biomaterials which will dramatically affect 
the feasibility of lyophilization as technique intended for long term storage of 
encapsulated therapeutics. 
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Figure 2.1 Light microscope and SEM images of empty alginate microcapsules.  
(A) Microcapsules before lyophilization in a hydrated form and spherical shape with a 
diameter of 200 m. (B) Lyophilized microcapsules that appear shrunk in a dehydrated 
form. (C) Lyophilized microcapsules were rehydrated by adding DI water where the 
microcapsules retain their spherical shape. Scale bars are 100 m (LM) and 10 m 
(SEM). 
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Figure 2.2 Release profiles comparison of loaded BSA within non-lyophilized and 
lyophilized alginate microcapsules at different incubation temperatures. 
All 2% alginate microcapsules were loaded with BSA at concentration of 1 mg/ml. The 
microcapsules were synthesized and gelled in a 0.15M CaCl2 bath at a pH of 7, a flow 
rate of 60 mm/hr, and a voltage of 6.0 kV. (A) Comparing release profiles of BSA in 
water at 37C between non-lyophilized and lyophilized microcapsules. (B) Comparing 
release profiles of BSA in water at room temperature between non-lyophilized and 
lyophilized microcapsules. Measurements were examined using Micro BCA protein 
assay at 562nm. 
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CHAPTER III 
THE EFFECT OF ELECTROSPRAY METHOD OF ENCAPSULATION 
ON THE VIABILITY OF LIVING CELLS WITHIN ALGINATE BASED 
MICROCAPSULES
2
  
3.1 Background 
 Currently available drug delivery systems cannot fulfill the demand of several 
diseases for tight regulation of therapeutic factors. Accordingly, cell therapy shows a 
potential to serve as a new approach of delivery systems for multiple diseases including 
neurodegenerative diseases, diabetes, and muscle diseases
48,90
. Genetically engineered 
cells, stem cells, and primary cells are the main focus of recent research studies with the 
aim of avoiding the implant rejection by host immune response and maintaining cell 
viability. Therefore, cell encapsulation emerges as a promising therapeutic strategy for 
targeted management of numerous health problems. The goal of cell encapsulation is to 
serve as a drug delivery tool, sustained release of therapeutics from encapsulated cells, 
and regenerative medicine tool, delivering cells to particular tissues
49,90
.Utilizing 
encapsulated cells as a therapeutic application was pioneered by Lim and Sun early in 
1980 when they demonstrated the ability of inducing normal glycemic levels in diabetic 
rats by implanting microencapsulated islets
91
. 
                                                          
2
 Parts of this chapter have been excerpted from the following research article: 
Belhaj M, Menon V, Rohrer B, Potts J. Alginate Microcapsule Technology and Impacts 
on Cell Therapy Development. Microsc Microanal. 2017;23(S1):1214-1215. 
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 Our aim in this work is utilizing A-PLO microcapsules as a carrier for different 
cell types genetically modified ARPE-19 cells, expressing inhibitory factor CR2 and 
CR2-fH, and skMDC cells that might be beneficial for future clinical approaches as 
delivery systems. 
3.2 Materials and Methods 
Cells Culture:  
Human retinal pigment epithelial cells (ARPE-19), cell line, were cultured in 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS). The medium was replaced every 2-3 days, and the cells were passaged after 
70%-80% confluence was reached. Cells were used between 24-27 passages. 
ARPE-19 cells were transfected using AAV- mediated delivery with plasmid 
constructs of CR2 and CR2-fH to express CR2 and CR2-fH proteins. These transfected 
cells were provided by our collaborators, Dr. Baerbel Rohrer’s lab, at The Medical 
University of South Carolina, Department of Ophthalmology. The cells were cultured in 
High glucose/without L-glutamine- Dulbecco's Modified Eagle Medium (Sigma 
Aldrich

) supplemented with10%  dialyzed FBS (Sigma Aldrich

), 2% Glutamine 
synthetase expression medium (GSEM- Sigma Aldrich

), and 0.28l/ml L-methionine 
sulfoximine (MSX- Sigma Aldrich

). The medium was replaced every 2-3 days, and the 
cells were passaged after 70%-80% confluence was reached. Cells were used between 
third and fifth passage. 
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Primary human skeletal muscle derived cells (skMDC) were obtained from Cook 
Myosite

( Pittsburgh, PA). skMDC were cultured in MyoTonic
TM
 basal medium 
supplemented with MyoTonic
TM
 growth supplement. Cells were cultured according to the 
supplier recommendations at 37 °C and 5% CO2 and maintained below 80% confluence. 
For differentiating the cells, the growth media will be replaced with MyoTonic
TM
 
differentiation media (DMD- Cook Myosite) after cells reach confluence, and exchanged 
after 2 days. The differentiation will be apparent within 3-4 days following replacing the 
media. 
Cell Encapsulation:  
Electrospray method of microencapsulation has been used to encapsulate the 
targeted cells. In this method, sodium alginate (Sigma-Aldrich) was mixed with DI water 
under sterile conditions at concentration of 2% w/v and purified by filtration at 0.2 mm. 
Alginate solution (300 l aliquots) were loaded into a 3cc syringe and attached to a 
syringe pump, and pumped through a needle (30G blunt tip; Small Parts, Inc., 
Logansport, IN, USA) to a gelling bath placed in a beaker below the syringe at 7 mm of a 
needle to bath spraying distance. The gelling bath contains a volume of 40 mL of 10 mM 
HEPES buffered saline containing 100 mM calcium chloride (CaCl2) (Sigma-Aldrich), 
and 0.5% w/v poly-L-ornithine (PLO) (Alfa Aesar) that forms a second coating to the 
microcapsules as one step method for adjusting the porosity. The needle tip connected to 
a high voltage generator while the gelling bath grounded. By applying high voltage 
between positive and grounded bath, alginate is extruded from the needle tip to the 
gelling bath where calcium ions (Ca2+) replace sodium ions (Na+) forming alginate 
microcapsules coated with PLO and cells mixed with alginate solution will be trapped 
 25 
inside the microcapsules. Cells were trypsinized, centrifuged, and washed with 10 mM 
HEPES buffered saline solution (pH 7.4), and a final cell concentration of 1x10
6
 in 
alginate solution were adjusted. Constant parameters of 60mm/hr flow rate and 6.0kV 
initial voltage were adjusted to produce microcapsules size of 200 m. The size of the 
microcapsules can be monitored by adjusting flow rate and voltage applied in which 
150 m diameter microcapsules can be retrieved by applying parameters of 30mm/hr 
and initial voltage 8kV. Formed microcapsules containing cells were washed with 
washing solution (10 mM HEPES buffered saline containing 1.5 mM CaCl2, pH 7.4) 
twice, and then incubated with suitable media in a humidified incubator at 37C and 5% 
CO2. 
Cell recovery:  
The cells were released from alginate microcapsules by adding 55 mM Sodium 
citrate in 10 mM HEPES buffered saline (pH 7.4) to the encapsulated cells with gentle 
shaking for 5 mins at room temperature. In this step, calcium ions will replace sodium 
ions in the microcapsule structure resulting in diluted sodium alginate and releasing the 
cells from the microcapsules. Furthermore, the cells were centrifuged at 1200 rpm for 5 
mins and incubated with media at 37C and 5% CO2 for 24 hrs. 
Cell viability (Live/Dead) assay:  
Encapsulated cells—after incubating the encapsulated cells for 24 hrs, 
approximately 30 microcapsules were washed twice with washing solution (10 mM 
HEPES buffered saline containing 1.5 mM CaCl2) and stained for live-dead viability. 
Live/Dead assay kit (Molecular Probes) was used to evaluate the viability of cells after 
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encapsulation. According to the manufacturer’s instructions, CalceinAM indicated viable 
cells by green fluorescence (excitation/emission 495/515 nm), whereas Ethidium 
homodimer-1 indicated dead cells by red fluorescence (excitation/emission 495/635 
nm). Encapsulated cells in washing solution were mixed with Calcein AM and Ethidium 
homodimer-1 at final concentrations of 2 M and 4 M respectively, and incubated for 
30-45 mins in dark at room temperature. After staining, microcapsules were washed 
twice with washing solution and imaged using Invitrogen EVOS FL Auto Cell Imaging 
System (Thermo Fisher Scientific, Waltham, MA). 
Encapsulated ARPE-19 cells in hydrogel— hydrogel was washed with PBS to 
remove any media traces and stained for encapsulated cells viability. Live/Dead assay kit 
(Molecular Probes) was used to evaluate the viability of cells after encapsulation and 
mixing with collagen hydrogel. According to the manufacturer’s instructions, CalceinAM 
indicated viable cells by green fluorescence (excitation/emission 495/515 nm), whereas 
Ethidium homodimer-1 indicated dead cells by red fluorescence (excitation/emission 
495/635 nm). A cocktail of Calcein AM and Ethidium homodimer-1 at final 
concentrations of 2 M and 4 M respectively was added to the hydrogel and incubated 
for 30-45 mins in dark at room temperature. After staining, excess amount of staining 
solution was washed with PBS and we imaged the encapsulated cells in the hydrogel 
using Invitrogen EVOS FL Auto Cell Imaging System. 
Immunofluorescence analysis of the skMDC:  
skMDCs were trypsinized from confluent plates and then grown overnight on 24 
well plate with initial seeding density of 10,000 cells per well.  Cells then were fixed with 
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2% formaldehyde for 5 minutes and permeabilized with PBS- 0.1%Triton X-100 for 10 
minutes. Fixed cells were washed with PBS and incubated at room temperature with 
Glycine then with 5% BSA/PBS for 30 minutes each in order to stop the fixation reaction 
using formaldehyde, and block non-specific protein binding accordingly. Cells after 
blocking were washed and incubated overnight at 4C with Desmine, MyoD, and Pax-7 
(Santa Cruz Technologies, Inc), 1:50 each. After washes, cells were incubated with 1:100 
Texas Red (TX)-conjugated goat anti-mouse antibody (Jackson ImmunoResearch 
Laboratories, West Grove, PA) together with DAPI for nuclear staining (Invitrogen/ Life 
Technologies). Samples were analyzed on Invitrogen EVOS FL Auto Cell Imaging 
System (Thermo Fisher Scientific, Waltham, MA) in the Instrumentation Resource 
Facility (IRF) at the USC School of Medicine. Cells were observed with a 10X objective 
lens, using a DAPI filter to visualize nuclei and a TX filter for Desmin, MyoD, and Pax7. 
Results were observed in three separate experiments. 
3.3 Results 
Encapsulation of ARPE-19 cells: 
 Electrospray method at voltage rate of 6.0 kV enabled us to encapsulate ARPE-19 
cells within 200 m A-PLO microcapsules as it is shown in Figure 3.1(B). Encapsulated 
cells were then incubated in 10% FBS DMEM media at 37C/ 5% CO2 for a period of 
time, microcapsules were imaged at different time points 3days, 6 days, and 20 days. As 
it is shown in Figure 3.1 the encapsulated cells were proliferating inside the 
microcapsules and appeared as clumps of cells. After 20 days of incubation, the 
microcapsules start to burst and cells find their way outside the microcapsules as shown 
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in Figure 3.1 (E). We revealed that FBS supplement in media has to be decreased from 
10% to 2% to slow down their proliferation to prevent losing the microcapsules.   
ARPE-19 cells viability test after encapsulation and their recovery from microcapsule 
structure: 
 After encapsulation and incubation in 10% FBS media for 3 days, cells were 
stained for live/ dead assay to evaluate their viability. Green color indicates viable cells 
whereas dead cells were stained red. In Figure 3.2 (A), Cells in green (viable) were more 
than dead cells (Red). 
 We examined the ability of the cells to be recovered back from microcapsules and 
their ability to be incubated and proliferate after exposure to high voltage rate during 
encapsulation. Encapsulated cells were incubated in 55 mM sodium citrate solution 
HEPES buffered saline. Sodium ions from the solution will replace calcium ions attached 
to alginate which will convert it into a soluble form and allow us to collect cells after 
centrifugation. Recovered cells were cultured back in media and incubated at 37C and 
5% CO2. Cell showed viability after being cultured back in their desired media, and we 
were able to passage it up to 3 times after recovery. 
Encapsulation of genetically modified ARPE-19 cells, viability, and recovery: 
Genetically modified ARPE-19 cells were provided by our collaborators from 
MUSC which expresses CR2 and CR2-fH proteins. Cells were encapsulated successfully 
as indicated in Figure 3.3 B and examined for viability where the viable cells were highly 
found in our sample; dead cells were barely found in our sample of live/dead assay as 
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shown in Figure 3.3 (A). Cells were then recovered from microcapsules and incubated in 
media as shown in Figure 3.3 (C) where the cells showed viability after recovery and they 
were passaged for up to 3 times.  
Encapsulation of skMDC cells, viability, recovery, and differentiation: 
  In Figure 3.4, skMDC cells encapsulated using the same method of encapsulation, 
and the encapsulated cells examined for viability where in Figure 3.4 (C) most  of the 
cells were green indicating its viability. 
 Cells were recovered and were recovered back in media as shown in Figure 3.4 
(D). In addition, a group of recovered cells were cultured in differentiating media Figure 
3.4 (E) where the cells showed viability in the new media and incubated to give them a 
chance to differentiate into skeletal muscles. 
Staining skMDC cells for myogenesis markers Desmin, MyoD, and Pax-7: 
 The main purpose of staining the cells for myogenesis markers is to examine the 
effect of encapsulation process has on the cell viability and metabolic activity. Staining 
skMDC cells against the myogenic markers showed that the cells from the entire 3 group: 
Control (before encapsulation), recovered, cells in differentiation media (differentiated), 
were able to express MyoD, desmin, and Pax7. Nuclei were stained blue (Dapi) while the 
targeted protein stained in red as it shown in Figure 3.5. 
 Freezing the encapsulated cells was another aspect that we utilized with ARPE-19 
cells. After encapsulation and incubation in media for 3 days, we changed culture media 
to a freezing media were the encapsulated cells mixed with and prepared for freezing. 
 30 
Vials of encapsulated cells were stored in Mr. Frosty and kept at -80C for up to one 
week. Finally, the encapsulated cells were thawed and cultured back in supplemented 
media, and then they were tested for viability using live/dead assay. As shown in Figure 
3.8, the cells were stained in green indicating that their viability still preserved; red signal 
indicating dead cells was barely expressed. 
3.4 Discussion 
Since enhancement of A-PLO microcapsules is the main goal of this work, cell 
encapsulation is another approach in which we utilize our microcapsules to encapsulate 
different type of cells. The polymer membrane serves as immunoisolation barrier for the 
cells intended for applications as therapeutic delivery system and regenerative medicine. 
Indeed, there are some preliminary clinical studies of prolonged survival of cells; 
however, cell encapsulation technology has not yet accomplished the expected clinical 
advances
49,92
. Recently, a wide range of research studies focused on investigating the 
effects of different fabrication methods and variety of polymers on viability and 
effectivity of variety of encapsulated cells
47–50, 91–102
. In this work, we investigated the 
effect of electrospray method of fabrication on cells encapsulated in A-PLO. Cells used 
for this study were intended for therapeutic agent delivery system, ARPE-19/ CR2-fH, 
and for regenerative medicine, skMDC.  
Encapsulated ARPE-19 cells through our fabrication method showed that the 
viability and effectivity of cells was preserved after encapsulation in Figure 3.1 and 
Figure 3.2. Consequently, genetically modified ARPE-19 cells, steadily express CR2-fH 
protein, proved to be viable and effective after encapsulation in Figure 3.3. ARPE-
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19/CR2-fH cells were generated in order to develop innovative therapeutic tool targeting 
treatment for age-related macular degeneration (AMD). Factor H serve as an inhibitory 
agent of the alternative pathway (AP) of complement activation, whereas polymorphisms 
in FH are associated with AMD risk. CR2-fH, the novel recombinant form of fH, has 
found to be effective inhibitor in different AP-dependent disease models such as 
collagen-induced arthritis, and acute lung reperfusion injury. Importantly, CR2-fH has 
shown that it is able to reduce the choroidal neovascularization (CNV) in vitro when 
injected intravenously
105–109
. Encapsulated ARPE-19 cells expressing CR2-fH showed to 
be effective in vivo as therapeutic agent delivery system. It has been presented that CR2-
fH was secreted in the eye from the encapsulated cells after intravitreal injection, and was 
effective in reducing compliment activation and can decrease CNV in mouse
93
.  
Primary human skeletal muscle cells (skMDC) are considered and targeted for 
cell therapy
110
. Encapsulation of skMDC cells might be useful as a potential therapeutic 
tool for treatment of severe muscle diseases and conditions. The results of this study 
demonstrated that cells viability and morphology characteristics were preserved after 
encapsulation in Figure 3.4. It was been showed that cells were recovered from 
microcapsules in which it continue to proliferate indicating that encapsulation process did 
not affect its biological characteristics. In addition, cell staining for the expression of 
myogenic markers such as desmin, MyoD, and Pax-7 showed that the cells in all the 
samples were able to express the targeted proteins Figure 3.5, 3.6, and 3.7 to proof that 
encapsulation technique does not affect the metabolic activity of encapsulated cells. 
Moreover, we showed in this work that cryopreservation of A-PLO encapsulated 
cells is a feasible for future therapeutics delivery and regenerative medicine projects. 
 32 
Previous research studies have been demonstrated that cryopreservation is a promising 
approach for preserving encapsulated cells for future optimization
101
. Encapsulated 
ARPE-19 cells have been shown to preserve the viability and biological activity after 
cryopreservation Figure 3.8. The goal of this approach was to generate the foundation for 
cryo-banking for future utilization of encapsulated cells in regenerative medicine and 
therapeutics delivery projects. 
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Figure 3.1 Effect of electrospray method on encapsulation of ARPE-19 cells. 
(A) ARPE-19 cells cultured in DMEM media. (B) Encapsulated cells at initial 
concentration of 1x106 cells/ ml after 1 hour of encapsulation. (C) Cells after 3 days of 
encapsulation. (D) Cells continue to grow inside the microencapsulation after 6 days of 
incubation in media. (E) Microcapsules became full of growing cells after 20 days of 
incubation in 10% FBS media. Scale bars = 100 microns.  
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Figure 3.2 Viability of ARPE-19 cells after encapsulation and Recovery. 
(A) Live/ dead staining performed on encapsulated cells after 3 days of encapsulation. 
Viable cells stained in green (CalceinAM), whereas cells in red (Ethidium homodimer) 
indicates cells with massive membrane damages. (B) ARPE-19 cells after encapsulation 
and before recovery. Cells were recovered from microcapsules using sodium citrate 
solution. The recovered cells have been passaged up to 3. Scale bars = 100 microns. 
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Figure 3.3 Viability of ARPE-19/CR2-fH cells after encapsulation and Recovery. 
(A) Live/ dead staining performed on encapsulated cells after 3 days of encapsulation. 
Viable cells stained in green (CalceinAM), whereas membrane damaged (dead) cells in 
red (Ethidium homodimer). (B) ARPE-19 cells after encapsulation and before recovery. 
Cells were recovered from microcapsules using a sodium citrate dissolving solution. The 
recovered cells have been passaged up to 3 times. Scale bars = 100 microns.  
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Figure 3.4 Viability of skMDC cells after encapsulation and Recovery. 
(A) skMDC cells cultured in supplemented MyoTonic media. (B) Encapsulated skMDC 
cells at initial encapsulation concentration of 1x106 cells/ml. (C) Encapsulated cells after 
3 days of encapsulation were stained with CalceinAM (2 M/ Green) and Ethidium 
homodimer (4 M/Red). Viable cells stained in green whereas dead cells in red. (D) 
skMDC were recovered from microcapsule structure using citrate sodium solution and 
cultured back into supplemented MyoTonic media. (E) A Group of recovered cells was 
cultured in differentiation media to allow them to differentiate and change phenotype. 
Scale bars = 100 microns. 
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Figure 3.5 The effect electrospray method of encapsulation on Desmin expression in 
skMDC cells. 
Control cells (before encapsulation), recovered, and differentiated cells were probed for 
DAPI (Blue) and desmin (Red). Scale bars = 100 microns. 
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Figure 3.6 The effect electrospray method of encapsulation on MyoD expression in 
skMDC cells. 
Control cells (before encapsulation), recovered, and differentiated cells were probed for 
DAPI (Blue) and MyoD (Red). Scale bars= 100 microns. 
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Figure 3.7 The effect electrospray method of encapsulation on Pax-7 expression in 
skMDC cells.  
Control cells (before encapsulation), recovered, and differentiated cells were probed for 
DAPI (Blue) and Pax-7 (Red). Scale bars = 100 microns. 
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Figure 3.8 Viability of encapsulated ARPE-19 cells after cryopreservation.  
(A) Encapsulated cells thawed after freezing at -80C for 1 week. (B) Encapsulated cells 
were tested for their viability after freezing. Viable cells were stained in Green 
(CalceinAM), and dead cells were stained in red (Ethidium homodimer). Scale bars = 100 
microns. 
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CHAPTER IV
3
 
ENCAPSULATED CELL TECHNOLOGY-BASED DELIVERY OF A COMPLIMENT 
INHIBITOR REDUCES CHOROIDAL NEOVASCULARIZATION IN A MOUSE 
MODEL 
4.1 Background 
 Age-related macular degeneration (AMD) is a slowly progressing condition that is 
classified according to the pathological mechanism into two categories, wet and dry 
AMD.   In wet AMD, fluid accumulates in the subretinal space due to choroidal blood 
vessels invasion through damaged blood barrier (BRB), and the fluid accumulation could 
cause retinal detachment that consequently lead to photoreceptor deterioration as 
complications of untreated condition. On the other hand, the pathological mechanisms of 
dry AMD are still not clearly understood. The main characteristics of dry AMD are 
degeneration of retinal pigment epithelium (RPE) and choriocapillaries that correlates to 
the loss of photoreceptor cells. Involvement of genetic and environmental risk factors are 
responsible on the complexity of AMD
111
. Wet AMD occurrence has been showed to be 
associated with single nucleotide polymorphisms (SNPs) in vascular endothelial growth 
factor (VEGFa), VEGFR2 receptor, and genes in the proliferation subpathway
112–115
; 
however, there is no clear pharmacogenetic association in anti-VEGF therapy between 
patient’s response to the treatment and patient’s VEGFa or VEGFR2 SNPs116,117. 
                                                          
3
 This chapter have been excerpted from the following research article: 
Annamalai B, Parsons N, Belhaj M, Brandon C, Potts J, Rohrer B. Encapsulated Cell 
Technology-Based Delivery of a Complement Inhibitor Reduces Choroidal 
Neovascularization in a Mouse Model. Transl Vis Sci Technol. 2018;7(2):3-3. 
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In addition to the multiple SNPs in genes of the complement pathway including 
polymorphisms in Y402H variant in the complement inhibitor factor H (CFH) which are 
linked with an increased risk of developing AMD
118
. According to association between 
AMD and Y402H, this study focused on investigating complement activation 
mechanisms in AMD models as well as examining improvements in complement 
therapeutics for treatment of AMD pathologies. 
  The complement system is a part of innate immune system that is activated in 
response to stress and/or injury stimulators. The activation of the complement systems 
followed by multiple biological molecules activation cascade including C3a and C5a 
(anaphylatoxins), opsonins C3d and C3dg (opsonization of damaged cells), membrane 
attach complex (MAC- lysis of cells)
119
. A complement inhibitor molecule (CR2-fH) has 
been developed and effectively inhibits complement activation at RPE levels in vitro in 
AMD models
120–122
. In addition, CR2-fH has been shown via in vitro models that it was 
effective in reducing choroidal neovascularization (CNV) development by suppressing 
complement activation and VEGF production
123–125
. Moreover, CR2-fH has shown 
effectivity as an inhibitor indifferent AP dependent disease conditions such as collagen 
induced arthritis, and acute lung and ischemia perfusion injury
126,127
. The inhibitory 
activity of CR2-fH is prompted due to presence of AP-inhibitory domain that linked to a 
complement receptor (CR2) and targets the inhibitor fH to bind complement activation 
products
128
. Importantly, the efficacy and safety of subretinal administration of AAV 
vector encoding the CR2-fH inhibitor has been confirmed in mouse model of CNV
129
. In 
the current study, efficacy of delivering CR2-FH using encapsulation technique to 
encapsulate genetically modified ARPE-19 cells has been examined in mouse CNV 
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model. The small size of produced alginate microcapsules is required for intravitreal 
injections into the eye of an experimental mouse. 
4.2 Materials and Methods 
Cells Culture:  
ARPE-19 cells, a human RPE cell line that express the differentiated phenotype 
of RPE cells.  The plasmid constructs of CR2 and CR2-fH were transfected into ARPE-
19 cells with FuGene HD transfection reagent according to the manufacturer’s 
instructions (Roche Applied Science, Indianapolis,IN). Stable expression in a mixed 
population was produced by L-methionine sulfoximine antibiotic selection. Secreted 
protein into apical and basal compartments was monitored in polarized RPE grown on 
transwell plates
121
. The molecular weight of CR2-fH was examined using sodium 
dodecyl sulfate acrylamide gel electrophoresis (SDS-PAGE; data not shown). The cells 
were cultured in High glucose/without L-glutamine- Dulbecco's Modified Eagle Medium 
(Sigma Aldrich

) supplemented with10%  dialyzed FBS (Sigma Aldrich

), 2% 
Glutamine synthetase expression medium (GSEM- Sigma Aldrich

), and 0.28l/ml L-
methionine sulfoximine (MSX- Sigma Aldrich

). The medium was replaced every 2-3 
days, and the cells were passaged after 70%-80% confluence was reached. Cells were 
used between third and fifth passage. 
Cells Encapsulation:  
Electrospray method of microencapsulation has been used to encapsulate the 
targeted cells. In this method, sodium alginate (Sigma-Aldrich) was mixed with DI water 
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under sterile conditions at concentration of 2% w/v and purified by filtration at 0.2 mm. 
Alginate solution (300 l aliquots) were loaded into a 3cc syringe and attached to a 
syringe pump, and pumped through a needle (30G blunt tip; Small Parts, Inc., 
Logansport, IN, USA) to a gelling bath placed in a beaker below the syringe at 7 mm of a 
needle to bath spraying distance. The gelling bath contains a volume of 40 mL of 10 mM 
HEPES buffered saline containing 100 mM calcium chloride (CaCl2) (Sigma-Aldrich), 
and 0.5% w/v poly-L-ornithine (PLO) (Alfa Aesar) that forms a second coating to the 
microcapsules as one step method for adjusting the porosity. The needle tip connected to 
a high voltage generator while the gelling bath grounded. By applying high voltage 
between positive and grounded bath, alginate is extruded from the needle tip to the 
gelling bath where calcium ions (Ca2+) replace sodium ions (Na+) forming alginate 
microcapsules coated with PLO and cells mixed with alginate solution will be trapped 
inside the microcapsules. Cells were trypsinized, centrifuged, and washed with 10 mM 
HEPES buffered saline solution (pH 7.4), and a final cell concentration of 1x10
6
 in 
alginate solution were adjusted. Constant parameters of 60mm/h flow rate and 8.0 kV 
voltage were adjusted to produce microcapsules size of 150 m. Formed microcapsules 
containing cells were washed with washing solution (10 mM HEPES buffered saline 
containing 1.5 mM CaCl2, pH 7.4) twice, and then incubated with suitable media in a 
humidified incubator at 37C and 5% CO2. 
Cells Recovery:  
The cells were released from alginate microcapsules by adding 55 mM Sodium 
citrate in 10 mM HEPES buffered saline (pH 7.4) to the encapsulated cells with gentle 
shaking for 5 mins at room temperature. In this step, calcium ions will replace sodium 
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ions in the microcapsule structure resulting in diluted sodium alginate and releasing the 
cells from the microcapsules. Furthermore, the cells were centrifuged at 1200 rpm for 5 
mins and incubated with media at 37C and 5% CO2 for 24 hrs. 
Cells Viability (Live/Dead) Assay:  
After incubating the encapsulated cells for 24 hours, approximately 30 
microcapsules were washed twice with washing solution (10 mM HEPES buffered saline 
containing 1.5 mM CaCl2) and stained for live-dead viability. Live/Dead assay kit 
(Molecular Probes) was used to evaluate the viability of cells after encapsulation. 
According to the manufacturer’s instructions, CalceinAM indicated viable cells by green 
fluorescence (excitation/emission 495/515 nm), whereas Ethidium homodimer-1 
indicated dead cells by red fluorescence (excitation/emission 495/635 nm). 
Encapsulated cells in washing solution were mixed with Calcein AM and Ethidium 
homodimer-1 at final concentrations of 2 M and 4 M respectively, and incubated for 
30-45 mins in dark at room temperature. After staining, microcapsules were washed 
twice with washing solution and imaged using Invitrogen EVOS FL Auto Cell Imaging 
System (Thermo Fisher Scientific, Waltham, MA). 
Microcapsule injections:  
 C57BL/6J mice 8-10 weeks of age of both sexes were used in this study (Jackson 
Laboratory, Bar Harbor, ME) that were bred in the facility animal house. All the 
experiments were carried out in compliance with the Guide for the ARVO Statement for 
the Use of Animals in Ophthalmic and Vision Research and were approved by the 
Animal Care and Use Committee at the Medical University of South Carolina. Prior to 
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intravitreal injections, mice were placed under using an anesthesia mixture of (xylazine 
and ketamine, 20 and 80 mg/kg, respectively) applied by intraperitoneal injection. 
Phenylephrine HCL (2.5%) and atropine sulfate (1%) were used to dilate the mouse’s 
pupils. Under dissecting microscope, an amount of 1 L of DMEM containing 
microcapsules with CR2-fH- or CR2-expressing ARPE-19 cells, native ARPE-19 cells, 
or no content was injected intravitreally with a 27G needle attached to a Hamilton syringe 
angled at 45-degree during the injection to avoid the lens. Before injecting the 
microcapsules, the sclera was punctured at the limbus with a 25G needle. Post injection, 
antibiotic ointment was applied to the animals’ eyes. 
Laser CNV:  
 Argon laser photocoagulation (532 nm, 100-lm spot size, 0.1- second duration, 
100 mW) was used one month post injection to create four laser spots around the optic 
nerve of each eye
124
. Bruch's membrane (BrM) rupture was confirmed by bubble 
formation at the laser burn site where those lesions only were used for lesion growth 
assessment
130
. Five days post CNV induction, mouse eyes were imaged using optical 
coherence tomography (OCT) before scarifying the animals on day 6 for tissue 
collection. 
Dot blot and Western Analysis:  
 Examining CR2-fH production from transfected cells—Cell lysates were 
collected after centrifugation (20,000g for 30 minutes at 48C). 25 l of total protein was 
loaded into 96- well plate and samples were transferred on a nitrocellulose membrane 
using the Bio-Dott Microfiltration Apparatus (Bio-Rad Laboratories, Inc. Hercules, CA). 
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The dotted membrane blocked in 5% nonfat milk in TBST buffer for 2 hours at room 
temperature after being washed with Tris-buffered saline and 0.1% Tween 20 (TBST) 
wash buffer. After blocking, the membranes were incubated overnight with primary 
antibody against CR2 at 1:1000 dilutions in 5% nonfat milk/ TBST. Horseradish 
peroxidase- conjugated secondary antibody (anti-rat; Santa Cruz Biotechnology, Inc., 
Dallas, TX) was used for visualization followed by incubation with Claritye Western 
ECL Blotting Substrate (Bio-Rad Laboratories, Inc.). 
Examining antibody generation in mice against secreted CR2-fH following 
intravitreal administration of ARPE-19 cells—Supernatants from CR2-fH-expressing 
cells were added to Laemmli sample buffer and boiled. Two different concentrations of 
the samples were separated electrophoretically using 4%–20% Criterione TGXe Gels 
(Bio-Rad Laboratories, Inc.). Proteins were then electro-transferred to PVDF membranes, 
and incubated with primary antibody against CR2, or serum (1:50) from mice treated 
with intravitreal CR2- or CR2-fH microcapsules. Horseradish peroxidase-conjugated 
secondary antibody (antimouse IgG and IgM; Santa Cruz Biotechnology) was used for 
visualization followed by incubation with Claritye Western ECL Blotting Substrate and 
chemiluminescent detection (Bio-Rad Laboratories, Inc.). 
Immunohistochemistry:  
 Tissue samples of eye lens and anterior chamber were removed from eyecups 
which was collected as showed in previous study
124
, and the samples were then fixed 
overnight with 4% paraformaldehyde (PFA). After thoroughly washing in PBS, samples 
were embedded in Neg-50 cutting medium (Richard-Allen Scientific; Thermo Fisher 
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Scientific) and sectioned into 14-m sections using a cryostat. Blocking solution 
consisting of (10% normal goat serum, 3% bovine serum albumin factor V, and 0.4% 
Triton-X in PBS) was used to block the sections before staining overnight with (1:200) 
CR2 (7G6) antibody at 4C. after washing the stained sections with blocking solution, 
secondary antibody was added (Alexa Fluor 488 goat anti-mouse IgG; 1:500; Invitrogen) 
and mounted using Fluoromount (Southern Biotechnology Associates, Inc., Birmingham, 
AL). Images were obtained by fluorescence microscope (Zeiss, Thornwood, NY). 
Optical Coherence and Tomography:  
 SD-OCT Bioptigent Spectral Domain Ophthalmic Imaging System (Bioptigen, 
Inc., Durham, NC) was used to visualize the injected microcapsules in the eye and to 
analyze CNV lesion size after 5 days of laser treatment as has been described in previous 
studies
131,132
. For the analysis of CNV lesion, rectangular volume scan images set at 1.63 
1.6 mm were acquired which consists of 100 B-scans (1000 A-scans per B scan)as well 
as measurements of cross-sectional area of the lesion using the en-face fundus 
reconstruction tool. The center of the lesion was determined passing through the RPE-
BrM rupture with the axial interval positioned at the level of the RPE/choroid complex as 
described in previous work
133
. Image J software for date analysis (Wayne Rasband, 
National Institutes of Health, Bethesda, MD; available online) was used to measure the 
area around the hyporeflective spot produced on the fundus image, with vertical calipers 
set at 0.100 mm at the site of each lesion. 
 
 
 49 
C3a ELISA:  
 Mouse complement C3a ELISA (LifeSpan Biosciences, Inc., Seattle, WA) was 
used to perform C3a ELISA according to the manufacturer’s protocol.  The RPE/ choroid 
tissues were ultrasonicated with 500 L ice cold PBS (lysing process) after being 
thoroughly rinsed with ice cold PBS to remove excess blood. The homogenized sample 
was centrifuged at 5000g for 5 minutes, and then the assay performed according to the 
manufacturer’s instructions. Standards of C3a were used along with samples, and the 
absorbance was read at 450 nm using microplate reader. 
Statistics:  
 Unpaired t-tests was used for single comparison, and ANOVA (Fisher PLSD) was 
used for in-between group analysis with P value = 0.05 for significance (StatView, Cary, 
NY). Data are reported as mean ± SEM. 
4.3 Results 
 Encapsulation of genetically modified ARPE-19 cells—secretion of CR2 and 
CR2-fH was confirmed by dot analysis using collected supernatants from cells grown as 
stable monolayers on transwell plates as shown in Figure 4.1 (D). Encapsulation of 
genetically modified ARPE-19 cells within 2% alginate microcapsules was successfully 
accomplished and it has been confirmed by brightfield microscopy Figure 4.1 (A). 
Viability of encapsulated cells post encapsulation was assessed using live dead assay that 
showed a viability of 90% of encapsulated cells Figure 4.1 (C). After dissolving the 
microcapsule structure using sodium citrate solution, ARPE-19 cells viability has been 
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assessed by incubating the cells back into their desired media where they have been 
grown for 90% confluency Figure 4.1 (B).  
 Delivery of encapsulated ARPE-19 cells intravitreally—the microcapsules size 
was adjusted through the encapsulation method to produce microcapsules at an 
approximate size of 150 l as an optimum size. The optimum size was ideal to be 
injected through 27G needle which its inner diameter 210m, and to minimize the 
microcapsules during intravitreal injection. OCT imaging was performed after injecting 
the microcapsules in the vitreous of mouse’s eye to examine the presence of intact 
microcapsules in that area as indicated in Figure 4.2 (A). In addition, presence of CR2-
FH in the microcapsules as well as its secretion into the vitreous and retinal tissue has 
been confirmed using immunohistochemistry Figure 4.2 (B). Moreover, it has been 
confirmed that CR2-fH specifically retained in CNV injury site compared to sites without 
CNV lesions by dot blot analysis of RPE/choroid fractions as shown in Figure 4.2 (C) 
and as previously reported in previous study
134
. Examining antibody production against 
secreted CR2-fH which might access the blood stream has been performed. Mouse serum 
was collected after 1 month of microcapsules injection and tested for anti-CR2-fH 
antibody production. It has been shown that neither IgG nor IgM antibodies recognizing 
CR2-fH could be identified in both CR2-fH microcapsules injected group or control 
group Figure 4.3. Similar results were previously reported when mice were systemically 
injected with CR2-fH protein
135
. 
 Effects of secreted CR2-fH on reducing complement activation and attenuating 
CNV development—the effect of secreted CR2-fH on CNV lesion size has been 
evaluated after 5 days of laser-induced photocoagulation. Experimental mice were 
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injected intravitreally with alginate microcapsules loaded with ARPE-19 expressing CR2, 
ARPE-19 expressing CR2-fH, native ARPE-19, or empty microcapsules. It has been 
reported in this study that lesion size in animals received microcapsules with cells 
expressing CR2-fh reduced significantly (P0.02) compared to other experimental animal 
groups as demonstrated in Figure 4.4 (A,B). Moreover, ELISA measurements showed 
significant reduction in C3a levels in mice injected with microcapsules containing cells 
expressing CR2-fH Figure 4.4 (C). This reduction was expected because it has been 
known previously that the presence of factor H prevents C3-convertase formation. On the 
other hand, animals injected with microcapsules loaded with cells expressing CR2, native 
cells, or empty microcapsules showed an increase in C3a in RPE/choroid fractions. 
4.4 Discussion 
 The focus of this study was to investigate the effectivity of encapsulation 
technique in encapsulating cells as cell therapy approach to deliver CR2-fH to the eye as 
a therapeutic strategy for complement dependent diseases. It has been demonstrated 
through this study that encapsulation technique can preserve the viability of encapsulated 
ARPE-19 cell within alginate based microcapsules. The encapsulated cells showed 
secretion activity of CR2-fH that is able to diffuse into the vitreous of the mouse while 
anti-CR2-fH antibody was not detected. Importantly, secretion of CR2-fH by 
encapsulated ARPE-19 cells in the eye showed a great effect on reducing CNV 
development as well as complement activation. Indeed, the obtained results propose the 
effectivity of encapsulated cell therapy as a therapeutic strategy in treating wet AMD. 
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 It has been recently discussed that the essential aim of encapsulated cells as a 
therapy approach is to provide a sustain release delivery of therapeutics secreted by 
encapsulated cells without triggering the immune response against it
136
. According to the 
present study, the viability of encapsulated cells was preserved and the cells were able to 
be recovered from the alginate microcapsules to continue proliferating after plating and 
incubating them back in media. Also, it was confirmed by dot blot analysis that cells 
secreted CR2-fH for 1 to 2 months after cells being encapsulated and injected; however, 
antibodies against CR2-fH were not generated by testing CR2-fH antibodies (IgG and 
IgM). On the other hand, antibodies formation against ARPE-19 epitopes have never 
been tested in this work because according to a number of clinical trials it has been 
shown that immunosuppressants are not required while utilizing devices loaded with 
ARPE-19 cells
137,138
.    
 In biotechnology industry world, Neurotech is a biotechnology company focused 
on the development of encapsulated cell therapy as a therapeutic approach for chronic 
eye diseases.  Neurotech has loaded ARPE-19 cells into a device (NT-501) that has been 
tested in the eye in which it is delivering CNTF and NT-503, a soluble anti-VEGF-R 
protein. NT-501 had a good safety results and ongoing trials in glaucoma and Macular 
Telangiectasia type 2 are taking place to deliver CNTF. However, delivering NT-503 
protein using this device has been discontinued in phase II trial because rescue 
medications were highly required in the treatment arm by a large number of patients 
according to Neurotech Company. Also, according to Neurotech, it is very important to 
consider the fact that ARPE-19 cells secrete not only therapeutic proteins but also other 
proteins consistently that might interfere with the efficacy of the targeted therapeutic 
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proteins. It has been demonstrated that ARPE-19 cells secret a diversity of proteins that 
are involved in maintenance and regulation of the complement pathway, extracellular 
matrix, inflammatory responses, and angiogenesis
139
. The quantity and the composition 
of proteins secreted can vary according to the eye under specific disease or treatment 
application technique; however, the effect of delivering encapsulated ARPE-19 cells on 
protein secretion and composition has not been determined in this study. Indeed in this 
work, data show the presence of ARPE-19 in the mouse eye do not interfere with the 
growth of CNV lesion, but also active CR2-fH showed a protective effect comparing to 
the inactive CR2, the native cells, or the empty microcapsules Figure 4.4 (B). Moreover, 
complement activation has not been affected by the presence of ARPE-19 cells in the 
mouse eye according to the measurements of complement C3a, and this has been 
determined through the effect of encapsulated native ARPE-19, encapsulated ARPE-19 
expressing CR2, and empty microcapsules Figure 4.4 (C). The concentration of 
microcapsules loaded with ARPE-19 expressing CR2-fH loaded reduced complement 
activation effectively to the base line levels. The preliminary data of this study showed 
that approximately 30 microcapsules were responsible on reducing the complement 
activation and interfere with CNV development. Accordingly, delivering the therapeutic 
dose of CR2-fH via cell encapsulation technique will promote normal functions of the 
complement system that is envision as a mediator as a global mediator in immune 
surveillance, cell homeostasis, and tissue development and repair
140
. 
 ARPE-19 cells have a potential of initiating complications on disease outcomes 
when they being used a therapeutic approach. The need of delivering anti-complement 
materials is a necessity, and AAV gene therapy is considered an attractive tool that has 
 54 
been utilized for disease models
141
. The expression of the inhibitor in dry or wet AMD 
should be inducible when required when new CNV lesion being developed, and it can be 
repressed once the inhibitory effect is no longer needed to avoid the toxic effects of 
excessive treatment. It has been demonstrated previously that using expression system 
that can be controlled exogenously, rapamycin or RU486 regulation, or endogenously, 
hypoxia response element (HRE), could be a feasible approach in controlling CR2-FH 
overtreatment, especially in case of HRE since hypoxia is highly correlated to wet 
AMD
142
. 
 This study showed that encapsulated cells therapy has been used to deliver the 
AP-complement inhibitor factor H using genetically modified ARPE-19 cells to the eye 
at complement activation sites. The inhibition of AP complement activation reduces 
complement activation, slows CNV development, and allows retention of physiological 
levels of complement required for cellular homeostasis and immune surveillance
140
.  
Future investigations are recommended to examine the feasibility of cell 
encapsulation-mediated therapeutic delivery of a complement inhibitor as a potential long 
term inhibition approach in the smoke-induced ocular model
125
, as well as  in dry AMD. 
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Figure 4.1 Encapsulation technique development to encapsulate genetically modified 
ARPE-19 cells to deliver CR2-fH. 
(A) Encapsulated ARPE-19 cells in culture. (B) Recovered cells after dissolving the 
microcapsule alginate structure and incubated in culture to examine viability. (C) Cell 
viability within the microcapsules was assessed using live/ dead assay where Calcein AM 
indicating live cells (Green) and Ethidium homodimer-1 indicating dead cells (Red). 
Secreted CR2 and CR2-fH towards both the apical and basal side from the stably 
transfected ARPE-19 cells that were grown as monolayers on transwell plates ( secretion 
assessed from three different cultures). 
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Figure 4.2 Assessment of delivering CR2-fH using encapsulation technique in the eye. 
(A) The microcapsules were detected in the eye using optical coherence tomography 
(OCT). (B) Immunohistochemistry was used to confirm production and diffusion of CR2-
fH protein from the microcapsules throughout the retina layers via antibody staining 
against CR2. Results were compared between uninjected control eyes and injected eyes 
where the staining was negative in the control. (C) A dot blot of RPE/choroid samples 
were used to detect CR2-FH after intravitreal injection of the microcapsules in the 
RPE/choroid region of the eye with CNV lesions or without. CR2-fH was detectable in 
the samples with CNV lesions comparing to the other group. Results are shown from 
more than three independent experiments. 
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Figure 4.3 Immune response measurements against CR2-fH produced in the eye. 
After one month of injecting encapsulated ARPE-19 cells expressing CR2 and CR2-fH, 
production of IgG or IgM were not detected. Two different concentrations of expressed 
CR2-fH were probed against anti-CR2 for the presence of CR2-fH in the supernatants in 
order to identify the size of the protein (positive control).Serum from both groups, 
experimental (S-E; injected with CR2-fH capsules) and control (S-E; age-matched 
animals without injections S-C), was used for probing at 1:50 followed by appropriate 
secondary antibodies. 
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Figure 4.4 Delivered CR2-fH through encapsulation technique reduces CVV and 
complement activation. 
Laser induced CNV was performed after one month of injecting encapsulated cells 
intravitreally. 5 days later, lesion spot sizes were analyzed using OCT and complement 
activation was assessed for anaphylatoxin C3a using ELISA. (A, B) CNV lesion sizes 
were reduced in the eyes of experimental group injected with encapsulated ARPE-19 
expressing CR2-fH compared to other groups, encapsulated cells expressing CR2, native 
ARPE-19 without cargo, or empty alginate microcapsules. (C) C3a levels in RPE/choroid 
fractions were elevated in animals injected with encapsulated ARPE-19 expressing CR2, 
encapsulated native ARPE-19, and empty microcapsules. Levels of C3a were reduced 
significantly in animal groups injected with encapsulated CR2-fH expressing cells. 
Control group represents animals with no CNV lesions. Data shown are average values 
(6SEM) (n ¼ 3–18 animals per condition as indicated). 
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CHAPTER V 
INVOLVEMENT OF HYDROGEL SYSTEMS IN ADVANCING 
ALGINATE BASED MICROCAPSULES 
 
5.1 Background 
 Hydrogels have been utilized as scaffold polymers in different approaches 
including therapeutic agent delivery and regenerative medicine. There are a variety of 
applications in which hydrogels have been targeted such as delivery agents for bioactive 
materials, as three-dimensional structures that can organize cells and direct the formation 
of a desired tissue with presence of specific stimuli, as well as their application as space 
filling agents
68
. Properties including mechanical properties, swelling, diffusion, and 
degradation are important to the hydrogel crosslinked structure in which they are control 
the hydrogel utilization for each specific approach
143
. Type I collagen has been used 
widely as a viable scaffold for various applications; however, collagen scaffold properties 
can vary according to the fabrication protocol used by different researchers. Collagen 
source and gelation pH are significant fabrication parameters that contribute to identify 
hydrogel properties and applications
68,76,144–148
. 
 The main goal of this study is developing new approach through embedding A-
PLO microcapsules in collagen hydrogel as an enhanced delivery system. Through this 
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study we will show the successful implementation of lyophilized microcapsules as well 
as our encapsulated cells within collagen hydrogel. 
5.2 Materials and Methods 
Collagen hydrogels:  
To prepare the hydrogels for incorporation of the lyophilized microcapsules, we 
used type I bovine collagen (Purecol, Advanced Biomatrix, San Diego, CA), 0.2N 
HEPES buffer pH9.0, and 10X Minimal Essential Medium (MEM) at proportions of 
8:1:1 accordingly. Lyophilized microcapsules were added immediately after mixing the 
hydrogel contents then aliquots of 300 l of the mix poured into 24 well plates. The plate 
was then incubated at 37C for 30 minutes to let it polymerize, then we added deionized 
water to keep hydrated. 
 To prepare the hydrogels for incorporation of the encapsulated ARPE-19 cells, we 
used type I bovine collagen (Purecol

, Advanced Biomatrix, San Diego, CA), 0.2N 
HEPES buffer pH9.0, and 10X Minimal Essential Medium (MEM) at proportions of 
8:1:1 accordingly. Encapsulated ARPE-19 cells were mixed with freshly prepared 
hydrogel gel after aspirating the media from the microcapsules. Appropriate aliquots 300-
500l of the mix were poured into 24 well plate; then incubated at 37C/ CO2 for 30 
minutes to let the hydrogel to polymerizing. Media was added after the hydrogel 
containing cells had been polymerized. 
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5.3 Results 
Lyophilized microcapsules in hydrogel: 
 Lyophilized microcapsules were mixed with freshly prepared type I collagen 
hydrogel and incubated for 30 minutes at 37C in order for the hydrogel to polymerize. 
Rehydration of lyophilized microcapsules were investigated under light microscope to 
verify that microcapsules were able to rehydrate within the hydrogel and retain their 
original shape (spherical) Figure 4.1 (B). 
Encapsulated cells in hydrogel: 
 Encapsulated cells were mixed with freshly prepared type I collagen hydrogel and 
incubated at 37C for 30 minutes. After polymerization of the hydrogel, we added media 
on the top of the hydrogel and we incubate it at 37C and 5% CO2 as it is shown in 
Figure 4.2 (B). Live/ dead assay was performed to test encapsulated cells viability within 
the hydrogel, and it was demonstrated that cells were still preserving their viability in 
Figure 4.2 (C) where live cells expressed in green. 
5.4 Discussion 
 Hydrogels are natural and synthetic three-dimensional systems with hydrophilic 
polymer chains which provide ability to hold high content of water. They have broad uses 
in biomedical research including drug delivery, regenerative medicine, and tissue 
engineering.
58,61,149–151
. The diversity of hydrogel applications is dependent upon the 
special traits of hydrogel that spans from biocompatibility, adjustable chemical 
properties, ability to mimic extracellular matrix, and serve as growth medium
151
 . As an 
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attempt to further improve A-PLO microcapsules for therapeutic applications, we utilized 
the lyophilized microcapsules and encapsulated cells to be mixed with type I collagen 
hydrogel. Our study shows that lyophilized microcapsules have the ability to rehydrate 
after being mixed with the hydrogel during its polymerization. The lyophilized 
microcapsules were empty; however we are demonstrating the effectiveness of the 
system as a tool for application in which the microcapsules can be filled with different 
therapeutic materials. Moreover, we also demonstrated the ability of the encapsulated 
ARPE-19 cells to be loaded into type I collagen hydrogels in which it can be used for 
regenerative medicine and as a delivery system. 
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Figure 5.1 Lyophilized microcapsules and their rehydration after mix with collagen 
hydrogel. 
(A) Microcapsules appear shrunk and dried after lyophilization. Lyophilized 
microcapsules rehydrated and returned their spherical shape again after mix with type I 
collagen hydrogel. Scale bars = 50 microns. 
 
 
 
 
 
Figure 5.2 Viability of encapsulated ARPE-19 cells embedded within type I collagen 
hydrogel. 
(A) Encapsulated ARPE-19 cells in DMEM media. (B) Encapsulated cells embedded in 
the hydrogel gel and incubated with media. (C) Encapsulated cells within the hydrogel 
were stained for their viability via live/dead assay. The Green was an indication of cell 
viability while the red indicated the damaged cells. Scale bars= 100 microns. 
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CHAPTER VI 
SUMMARY AND FUTURE WORK
 
Summary 
 Electrospray microencapsulation has been used in our lab previously to show 
enhanced wound healing in a rodent model.  The previous work concentrated on the 
encapsulation of a small peptide known as CT185; in addition, we have had success in 
encapsulating different constituents such as proteins, antimicrobial agents, and even cells. 
In this work, I was able to show several enhancements to the original encapsulation 
technique for both wound healing and cell therapy. I was able to lyophilize the alginate-
PLO microcapsules without damaging their morphology following rehydration with the 
addition of DI water or Tyrodes buffer. Interestingly the microcapsules regain their 
spherical shape with some surface irregularity. I was also able to show that addition of 
lyophilized microcapsules to a gelling collagen matrix also showed the ability to hydrate 
back into their original spherical shape. To investigate the process for cell based 
therapies, I was able to encapsulate various cell types using the same method of 
encapsulation by tweaking the voltages and flow rates for optimum cell viability, and 
showed the ability of the cells to survive the voltage applied during microencapsulation 
technique. Encapsulated cells (ARPE-19, genetically engineered ARPE-19, and skMDC) 
were tested for viability after encapsulation using live/ dead assay, and the cells types 
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were shown to be viable within the microcapsules. We took this to an in vivo model of 
age related macular degeneration (AMD) and showed that addition of genetically 
modified ARPE-19 cells expressing the protein CR2-fh was able to ameliorate the 
symptoms of AMD in a mouse model. To determine whether the encapsulation process 
had interfered with the cells proliferative ability, we tested the cells when dissolved from 
the capsules and demonstrated their ability to continue to proliferate in culture and were 
passaged multiple times thereafter. Finally, we showed that the skMDCs retained several 
key markers, Pax7, desmin and MyoD following dissolving and further culturing. 
Indicating that the encapsulation process is not affecting the cells proliferative 
capabilities nor losing their inherent genetic profile.  
 We also demonstrated our ability to cryopreserve the microencapsulated cells for 
a period that resembles long term storage for future experimental use, and showed their 
viability after thawing and culturing in media. We froze the encapsulated cells and stored 
them at both -80C and also liquid nitrogen. Cells frozen in both conditions showed the 
ability to regain their growth potential. Finally, encapsulated cells were incorporated 
successfully within type I collagen hydrogels where the cells preserved their viability 
while cultured within this system which can be further utilized for tissue engineering and 
sustain release delivery of therapeutics. 
Future Work 
 Presented here is a promising technique that can be tuned for its utilization 
according to each approach discussed in this study. Further investigations are needed for 
the effect of lyophilization on release profiles of materials such as CT1, and BSA 
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loaded A-PLO microcapsules; a complete and comprehensive analysis of loaded 
lyophilized microcapsules for their sustained release and therapeutic effect on wound 
healing needs further investigation. In the future encapsulation of multiple cell types in 
the capsules is planned. It’s believed that the cells interact in vivo could in fact be 
encapsulated to mimic their in vivo interactions. We would also begin examining the 
ability to further coat the microcapsules with antibodies to further target the addition of 
the microcapsules within the body to certain tissues or cells. Additionally, a single report 
exists of the ability to lyophilize microencapsulated cells. We plan to further our initial 
work to determine if this is another viable option of our system.  Finally, we plan to 
generate an animal model for skeletal muscle atrophy and/or degeneration and use our 
encapsulated skMDCs to fully evaluate the therapeutic potentials of encapsulating 
skMDC cells in these types of muscle diseases. Thus providing us a true bench top to 
bedside application in the future. 
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